Ultragenyx Pharmaceutical Inc. (RARE)

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

As of November 3, 2026, Ultragenyx Pharmaceutical Inc. (RARE) stock climbed to $16.79, up 3.01% (+$0.49) versus the previous close. On the day, shares have traded between $16.39 and $16.99. That puts RARE in the lower third of its 52-week range of $12.73 to $39.89. Ultragenyx Pharmaceutical Inc. operates in the pharmaceutical preparations space and carries a market capitalization of roughly $1.59 billion, with about 732.8K shares changing hands.

Latest RARE news

• Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Yahoo Finance· Oct 30, 5:53 PM ET
• Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out forYahoo Finance· Oct 28, 9:00 AM ETCTKB
• GSK (GSK) Q3 Earnings and Revenues Beat EstimatesYahoo Finance· Oct 28, 6:10 AM ETGSK
• Has The Story Under Krystal Biotech Stock Run Out?trefis.com· Oct 28, 4:22 AM ET
• Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate UpdateYahoo Finance· Oct 27, 4:05 PM ET
• Broadcom upgraded, HubSpot downgraded: Wall Street's top analyst callsYahoo Finance· Oct 27, 9:40 AM ET
• Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseYahoo Finance· Oct 27, 9:00 AM ET
• Sector Update: Healthcare Stocks Softer Monday AfternoonYahoo Finance· Oct 19, 1:52 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want RARE headlines, alerts and AI research in one place? Create a free account →

• $RARE NEW CORPORATE PRESENTATION

  @MrHankey69· Nov 3, 10:48 AM ET· Bullish

• $RARE just moving with XBI I want some good news today to go beyond

  @RonnySalts· Nov 3, 10:36 AM ET

• Ultragenyx $RARE terminated its Phase 2 GTX-102 Angelman study for lack of efficacy. The trial enrolled 55 patients. Q3 results are due today at 5:00 p.m. ET. Shares closed at $16.30 on Monday, below the SMA50 and below the SMA200, RSI 62. More details in our hub. Not investme…

  @Merlintrader· Nov 3, 9:06 AM ET

• $RARE they tell me the BIG DROP was an OVER REACTION wen the STOCK FELL by %50.well we will find out today the same day of USA ellections.CLOSE eye on aerly + last hour trades we might have some good NEWS.

  @porky1963· Nov 3, 6:01 AM ET

• $RARE Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday,…

  @Idontknownothing55· Nov 2, 2:21 PM ET· Bullish

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →